Chicago, IL – May 7, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S NVO, Honeywell International Inc. HON and American Tower Corp. AMT.
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Novo Nordisk, Honeywell and American Tower
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, Honeywell International Inc. and American Tower Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Slip Lower on Record Trade Deficit, Q1 Earnings
Today's Featured Research Reports
Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-44.9% vs. -6.9%). The company's failure to meet the weight-loss target with CagriSema twice caused Novo Nordisk a huge setback. Intense rivalry in the obesity sector also threatens its market share. Patent expiry and pricing pressure across the diabetes market remain a headwind.
Nevertheless, Novo Nordisk's diabetes drugs Ozempic and Rybelsus and obesity drug Wegovy are performing well, fueled by increasing demand. Label expansions in cardiovascular and other indications will likely boost sales. It has been tackling the supply constraints of Wegovy by making serious investments to ramp up production.
It is now indicated in the U.S. and the EU to also reduce heart risks, which is a huge boost. Novo Nordisk is also pursuing other indications like liver fibrosis and MASH for semaglutide.
(You can read the full research report on Novo Nordisk here >>>)
Honeywell'sshares have outperformed the Zacks Diversified Operations industry over the past year (+11.2% vs. +8.3%). The company's strength in the commercial aviation and building automation businesses augurs well for Honeywell. The Aerospace segment is particularly strong, driven by strength in the defense business and growth in air transport flight hours.
Strong demand across the commercial aviation aftermarket business is aiding the segment. The company also continues to reward shareholders, which adds to the stock's appeal. While acquisitions have expanded its product range and geographic reach, they have increased the company's balance sheet debt as well.
However, weakness in the Industrial Automation segment, due to lower demand for smart energy and thermal solutions, is worrisome. The weakened demand for personal protective equipment within the sensing and safety technologies business is also concerning. Foreign currency translation remains an overhang.
(You can read the full research report on Honeywell here >>>)
Shares of American Tower have outperformed the Zacks REIT and Equity Trust - Other industry over the past year (+27.5% vs. +13.9%). The company owns an extensive, geographically diversified communication real estate portfolio. Its first-quarter 2025 results reflect a rise in revenues, led by revenue growth in property and service segments.
With wireless carriers increasing capital expenditure due to rising wireless penetration, accelerated 5G network deployment efforts, and spectrum auctions, demand is likely to stay strong. The long-term leases with its tenants assure stable cash flows. Its continued efforts toward macro-tower investments to expand its global footprint and address the demand in these markets bode well for long-term growth.
A decent financial position supports its growth endeavors. However, customer concentration and consolidation are a concern in the wireless industry, and will likely weigh on top-line growth. It also faces headwinds from Sprint churn.
(You can read the full research report on American Tower here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
